Selective PPAR Modulation via Segmented Molecular Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for metabolic disorders and inflammatory diseases often have limitations in selectively targeting PPARα, PPARγ, and PPARδ receptors, leading to suboptimal efficacy and specificity.
Innovation Solution
Development of compounds, such as those described in Formula I, which exhibit pan-activity across PPAR family members or significant specificity to individual PPARs, allowing for targeted modulation of these receptors to treat various metabolic and inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat metabolic disorders and inflammatory diseases, then treatment can be provided, but selectivity in targeting PPARα, PPARγ, and PPARδ receptors is insufficient leading to suboptimal efficacy and specificity
Solution Approach 1:
The patent segments the PPAR receptor family into three distinct targets (PPARα, PPARγ, PPARδ) and develops compounds with selective affinity for each individual receptor subtype. This segmentation allows therapies to target specific PPAR isoforms based on the disease indication, improving both efficacy and selectivity rather than using non-selective agonists for all PPARs.
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular characteristics that confer selective binding to particular PPAR subtypes. Different chemical structures and functional groups are incorporated into compounds to create localized interactions with specific amino acid residues in the ligand-binding domains of PPARα, PPARγ, or PPARδ, thereby achieving subtype-selective modulation.
2Adaptability or versatility
If non-selective PPAR agonists are used, then broad coverage of metabolic pathways is achieved, but harmful effects occur including hepatotoxicity and peroxisome proliferation
Solution Approach 1:
The patent extracts the harmful effects associated with non-selective PPAR activation by removing compounds that cause hepatotoxicity and peroxisome proliferation from the therapeutic regimen. Instead, selectively selective agonists are used that activate only the desired PPAR subtype(s) responsible for beneficial metabolic effects while avoiding activation of PPARα, which mediates the toxic effects in humans.
Solution Approach 2:
The patent converts the potential harm of PPAR activation into benefit by selectively activating only the beneficial PPAR subtypes (PPARγ for insulin sensitivity, PPARδ for lipid metabolism) while avoiding activation of PPARα, which causes harmful effects. This selective approach harnesses the beneficial metabolic effects of PPAR activation without incurring the toxic consequences.
3Reliability
If selective PPAR agonists are developed, then efficacy and specificity are improved, but compound complexity increases
Solution Approach 1:
The patent achieves selectivity by modifying specific parameters of the compound molecules, such as the presence and position of particular functional groups, aromatic rings, and side chains. By systematically varying these molecular parameters, compounds are optimized for selective binding to specific PPAR subtypes. This approach allows control of selectivity through molecular design rather than requiring excessively complex multi-component structures.
Data Source
AI summary
Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ, wherein the compounds have the formula:wherein:X2 and X3 are independently CH or N; andone of X1 and X4 is N or CR4 and the other of X1 and X4 is N or CH.